Verastem (VSTM) Change in Accured Expenses (2011 - 2026)
Verastem (VSTM) recorded quarterly Change in Accured Expenses of -$3.1 million in Q1 2026, down 133.34% quarter-over-quarter from $9.2 million in Q4 2025, and down 215.05% on a YoY basis from $2.7 million in Q1 2025.
Verastem (VSTM) Change in Accured Expenses (2011 - 2026) Analysis & Trends
Verastem's Change in Accured Expenses history runs 16 years deep, the most recent figure standing at -$3.1 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 215.05% year-over-year to -$3.1 million; the TTM figure through Mar 2026 stood at $25.1 million (up 124.0% YoY), while the FY2025 annual figure was $30.8 million, up 285.46% from the prior year.
- Change in Accured Expenses was -$3.1 million for Q1 2026 at Verastem, down from $9.2 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $15.0 million in Q3 2025 to a low of -$3.1 million in Q1 2026.
- Historically, Change in Accured Expenses has averaged $2.2 million across 5 years, with a median of $1.6 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses slumped 292.62% in 2022, then jumped 2285.16% in 2025.
- A 5-year view of Change in Accured Expenses shows it stood at $195000.0 in 2022, then soared by 724.1% to $1.6 million in 2023, then surged by 134.41% to $3.8 million in 2024, then soared by 144.01% to $9.2 million in 2025, then plunged by 133.34% to -$3.1 million in 2026.
- The last three Change in Accured Expenses figures came in at -$3.1 million (Q1 2026), $9.2 million (Q4 2025), and $15.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Verastem | 407.42 Mn | 225.74 Mn | 15.90 Mn | -3.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.07 Mn |
| Mar 31, 2026 | -3.07 Mn |
| Dec 31, 2025 | 9.19 Mn |
| Dec 31, 2025 | 9.19 Mn |
| Sep 30, 2025 | 15.00 Mn |
| Sep 30, 2025 | 15.00 Mn |
| Jun 30, 2025 | 3.98 Mn |
| Jun 30, 2025 | 3.98 Mn |
| Mar 31, 2025 | 2.66 Mn |
| Mar 31, 2025 | 2.66 Mn |
| Dec 31, 2024 | 3.77 Mn |
| Dec 31, 2024 | 3.77 Mn |
| Sep 30, 2024 | 4.96 Mn |
| Sep 30, 2024 | 4.96 Mn |
| Jun 30, 2024 | -182,000.00 |
| Jun 30, 2024 | -182,000.00 |
| Mar 31, 2024 | -544,000.00 |
| Mar 31, 2024 | -544,000.00 |
| Dec 31, 2023 | 1.61 Mn |
| Dec 31, 2023 | 1.61 Mn |